AEON Financial Statements From 2010 to 2026
| AEON Stock | | | 1.24 0.11 9.73% |
AEON Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing AEON Biopharma's valuation are provided below:
Market Capitalization | Enterprise Value Revenue | Earnings Share |
We have found one hundred twenty available fundamental signals for AEON Biopharma, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate AEON Biopharma's prevailing
fundamentals against the trend between
2010 and 2026 to make sure the company can sustain itself in the future. As of the 7th of January 2026,
Market Cap is likely to drop to about 23
M. In addition to that,
Enterprise Value is likely to drop to about 37.1
MCheck out the analysis of
AEON Biopharma Correlation against competitors.
To learn how to invest in AEON Stock, please use our
How to Invest in AEON Biopharma guide.
AEON Biopharma Balance Sheet | | |
|
AEON Biopharma Income Statement | | |
|
AEON Biopharma Cash Flow Statement | | |
|
Financial Ratios | | |
|
AEON Biopharma Valuation Data | | |
|
AEON Fundamental Market Drivers
| Forward Price Earnings | 1.1577 |
| Cash And Short Term Investments | 13 K |
About AEON Biopharma Financial Statements
AEON Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how AEON Stock might perform in the future. Analyzing these trends over time helps investors make informed
market timing decisions. For further insights, please visit our
fundamental analysis page.
Pair Trading with AEON Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AEON Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AEON Biopharma will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to AEON Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AEON Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AEON Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AEON Biopharma to buy it.
The correlation of AEON Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AEON Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AEON Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AEON Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
When determining whether AEON Biopharma
offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AEON Biopharma's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aeon Biopharma Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Aeon Biopharma Stock: Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost
the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AEON Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share | Return On Assets |
The market value of AEON Biopharma is measured differently than its book value, which is the value of AEON that is recorded on the company's balance sheet. Investors also form their own opinion of AEON Biopharma's value that differs from its market value or its book value, called intrinsic value, which is AEON Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AEON Biopharma's market value can be influenced by many factors that don't directly affect AEON Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AEON Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine
if AEON Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AEON Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.